Sponsored by Academy for Continued Healthcare Learning
Supported by an educational grant from Merck & Company.
This activity will feature three faculty members who will discuss a patient case relating to the assessment and treatment of serious infections. Our expert faculty will discuss Gram-negative infections, diagnostic approaches, molecular epidemiology of antibiotic resistance, and new and emerging approaches to Gram-negative organisms. The purpose of this activity is to provide members of antimicrobial stewardship programs and clinicians who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance
This activity is intended for ID specialists, researchers, clinical microbiologists, hospitalists, internists, pharmacists and other healthcare professionals who care for patients at risk of serious infection
Upon proper completion of this activity, participants should be better able to:
Discuss the molecular epidemiology of antibiotic resistance in bacterial pathogens
Compare and contrast antibiotics currently in development for use against gram-negative pathogens
Describe strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance
Conflict of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Jason M. Pogue, PharmD, BCPS, BCIDP Clinical Assistant Professor of Medicine Wayne State University School of Medicine Detroit, MI
Dr. Pogue discloses the following: Consultant: Melinta, Merck, Nabriva, Shionogi, and Tetraphase Speakers Bureau: Melinta and Merck Grant Support: Merck
Patricia (Trish) Simner, PhD, D(ABMM) Director of Medical Bacteriology and Parasitology Laboratories Associate Professor of Pathology Johns Hopkins School of Medicine Baltimore, MD
Dr. Simner discloses the following: Consultant: Accelerate Diagnostics, CosmosID, OpGen Inc., and Roche Diagnostics Research Grants: Accelerate Diagnostics, Affinity Biosensors, Check-Points BV, Hardy Diagnostics, and OpGen Inc.
Pranita D. Tamma, MD, MHS Director, Pediatric Antimicrobial Stewardship Program Associate Professor of Pediatrics Johns Hopkins University School of Medicine Baltimore, MD
Dr. Tamma discloses the following: Research Grants: Merck
Accredited Provider Disclosure
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
Novel antibiotics and available antibiotics under investigation for use in different types of serious infections.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available and emailed, please be sure to check spam/junk mailbox. There is no fee to participate in the activity or for the generation of the certificate. Your certificate will be saved on the ACHL website and will not be available in your myCME History.